Global Insights: Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market Expected to Surpass $10.48 Billion by 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Are the Forecasted Growth Rate and Market Size of the Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
In recent times, there has been a robust growth in the market size of therapeutics for castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA). Projected growth is set to increase from $7.96 billion in 2024 to $8.43 billion in 2025, marking a compound annual growth rate (CAGR) of 5.9%. Factors contributing to this growth during the historic period include rising incidents of prostate cancer, heightened use of androgen deprivation therapy (ADT) resulting in resistance, increased access to targeted therapy options, enhanced diagnostic imaging capabilities, and an upsurge in healthcare investments towards oncology infrastructure.
The therapeutics market for castration-resistant prostate cancer (crpc) or hormone-refractory prostate cancer (hrpca) is projected to witness robust expansion in the forthcoming years, reaching $10.48 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The anticipated growth during the forecast period is due to the increased adoption of precision oncology and biomarker-focused treatments, an upsurge in demand for next-gen hormonal and radioligand therapies, expansion in clinical trial pipeline for advanced prostate cancer, a growing selection of targeted and immuno-oncology agents, and increasing requirement for personalized medicine approaches. Other forecast period trends include the development of combined immunotherapy regimens, the utilization of genomic profiling in clinical decisions, the incorporation of digital health monitoring tools for patients, advancements in bispecific T-cell engagers, and unfolding of tumor microenvironment regulators.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24495&type=smp
Which Factor Is Shaping The Future Of The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
The increase in the number of prostate cancer cases is predicted to bolster growth within the market for Castration-Resistant Prostate Cancer (CRPC) or Hormone-Refractory Prostate Cancer (HRPCA) therapies. Prostate cancer is a disease that forms in the prostate gland, a small gland situated below the bladder and in front of the rectum in males. The primary contributing factor to the uptick in prostate cancer is the aging population since the likelihood of contracting prostate cancer escalates significantly with advancing age. Therapeutics for Castration-Resistant Prostate Cancer (CRPC) or Hormone-Refractory Prostate Cancer (HRPCA) play a critical role in prostate cancer treatment as they target the disease in its more advanced stages when it is no longer responsive to typical hormone treatments. These treatments better patient prognoses by decelerating the pace of disease progression and managing symptoms, therefore improving life quality. To illustrate, the UK-based government department, the National Health Service, reported in November 2024 that new cases of prostate cancer in 2022 stood at 54,732, marking a rise of 11,354 cases in comparison to 2021. As such, the escalating prevalence of prostate cancer is fuelling the growth of the CRPC or HRPCA therapies market.
What Is The Segment-Wise Breakdown Of The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Market?
The castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market covered in this report is segmented –
1) By Therapy Type: Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy, Radiation Therapy
2) By Route Of Administration: Oral, Injectable, Intravenous
3) By End User: Hospitals, Oncology Centers, Ambulatory Surgical Centers, Other End Users
Subsegments:
1) By Hormonal Therapy: Androgen Receptor (AR) Inhibitors, Androgen Synthesis Inhibitors, Luteinizing Hormone-Releasing Hormone (LHRH) Agonists Or Antagonists, Gonadotropin-Releasing Hormone (GnRH) Agonists Or Antagonists
2) By Chemotherapy: Taxanes, Platinum-Based Agents, Other Chemotherapies
3) By Immunotherapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Cytokine Therapy, Adoptive Cell Therapy
4) By Targeted Therapy: Poly ADP-Ribose Polymerase (PARP) Inhibitors, Phosphoinositide 3-Kinase (PI3K) Or Protein Kinase B (PI3K) Or Mammalian Target Of Rapamycin (mTOR) Inhibitors, Tyrosine Kinase Inhibitors (TKIs), Deoxyribonucleic Acid Damage Response (DDR) Inhibitors
5) By Radiation Therapy: External Beam Radiation Therapy, Brachytherapy, Radiopharmaceuticals
Which Trends Are Redefining The Future Landscape Of The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Industry?
Top firms active in the therapeutics market for hormone-refractory prostate cancer (HRPCA) or castration-resistant prostate cancer (CRPC) are directing their efforts towards creating novel products and securing necessary approvals, such as dual-action tablets, to improve the effectiveness of treatments and patient outcomes. These tablets are modern formulations that combine a pair of therapeutic elements in one dose, aiming to address multiple pathways in CRPC treatment concurrently. In a case in point from August 2023, Janssen Pharmaceuticals, a pharmaceutical firm hailing from Belgium, gained clearance from the U.S. Food and Drug Administration for Akeega, an innovative tablet designed for adults inflicted with BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Akeega merges a CYP17 inhibitor (abiraterone acetate) with a PARP inhibitor (niraparib), to target specifically BRCA mutation-carrying patients. When used in conjunction with prednisone, this drug vastly boosts radiographic progression-free survival (rPFS), surpassing the effects of standard hormonal therapy.
Which Companies Hold The Largest Market Share In The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Sector?
Major companies operating in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market are Pfizer Inc., Johnson And Johnson, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Lantheus Holdings Inc., POINT Biopharma Global Inc., Clovis Oncology Inc., Arvinas Inc., Clarity Pharmaceuticals Ltd, Modra Pharmaceuticals B.V., Oncternal Therapeutics Inc., Zenith Epigenetics Ltd., ESSA Pharma Inc.
Get The Full Report Here:
How Does Regional Performance Compare Across The Castration-Resistant Prostate Cancer (CRPC) Or Hormone-Refractory Prostate Cancer (HRPCA) Therapeutics Industry?
North America was the largest region in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the castration-resistant prostate cancer (CRPC) or hormone-refractory prostate cancer (HRPCA) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=24495&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
